AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has been given an average recommendation of “Hold” by the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $4.38.

AVEO has been the subject of a number of recent analyst reports. Seaport Global Securities reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a research report on Friday, October 6th. B. Riley initiated coverage on shares of AVEO Pharmaceuticals in a research report on Monday, November 13th. They set a “buy” rating and a $5.00 price target for the company. initiated coverage on shares of AVEO Pharmaceuticals in a research report on Wednesday, November 15th. They set a “buy” rating and a $5.00 price target for the company. Zacks Investment Research cut shares of AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, December 6th. Finally, BidaskClub cut shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 9th.

Shares of AVEO Pharmaceuticals (AVEO) traded down $0.02 on Friday, hitting $2.82. 1,370,000 shares of the company’s stock were exchanged, compared to its average volume of 1,540,000. AVEO Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $4.24. The firm has a market capitalization of $333.63, a PE ratio of -3.97 and a beta of 1.14. The company has a current ratio of 2.33, a quick ratio of 2.33 and a debt-to-equity ratio of -0.32.

AVEO Pharmaceuticals (NASDAQ:AVEO) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. equities analysts forecast that AVEO Pharmaceuticals will post -0.66 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in AVEO. RA Capital Management LLC acquired a new position in shares of AVEO Pharmaceuticals in the second quarter valued at approximately $18,727,000. Vanguard Group Inc. grew its holdings in shares of AVEO Pharmaceuticals by 48.6% in the second quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after purchasing an additional 1,162,232 shares in the last quarter. EAM Investors LLC acquired a new position in shares of AVEO Pharmaceuticals in the second quarter valued at approximately $1,979,000. Essex Investment Management Co. LLC acquired a new position in shares of AVEO Pharmaceuticals in the third quarter valued at approximately $550,000. Finally, OxFORD Asset Management LLP acquired a new position in shares of AVEO Pharmaceuticals in the third quarter valued at approximately $228,000. Hedge funds and other institutional investors own 50.91% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “AVEO Pharmaceuticals, Inc. (AVEO) Receives $4.38 Consensus PT from Analysts” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/01/17/aveo-pharmaceuticals-inc-aveo-receives-4-38-consensus-pt-from-analysts.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.